Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel

References

• Alibolandi M, Ramezani M, Sadeghi F, Abnous K, Hadizadeh F. 2015. Epithelial cell adhesion molecule aptamer conjugated PEG–PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro. Int J Pharm. 479(1):241–251.
   PubMed Web of Science ®Google Scholar
• Badran MM, Alomrani AH, Harisa GI, Ashour AE, Kumar A, Yassin AE. 2018. Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability. Biomed Pharmacother. 106:1461–1468.
   PubMed Web of Science ®Google Scholar
• Banerjee SR, Foss CA, Horhota A, Pullambhatla M, McDonnell K, Zale S, Pomper MG. 2017. 111In- and IRDye800CW-labeled PLA–PEG nanoparticle for imaging prostate-specific membrane antigen-expressing tissues. Biomacromolecules. 18(1):201–209.
   PubMed Web of Science ®Google Scholar
• Bharali DJ, Pradhan V, Elkin G, Qi W, Hutson A, Mousa SA, Thanavala Y. 2008. Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine. 4(4):311–317.
   PubMed Web of Science ®Google Scholar
• Bharali DJ, Sudha T, Cui H, Mian BM, Mousa SA. 2017. Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomed Nanotechnol Biol Med. 13(1):263–273.
   PubMed Web of Science ®Google Scholar
• Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC. 2007. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 28(5):869–876.
   PubMed Web of Science ®Google Scholar
• de Franciscis V. 2018. Challenging cancer targets for aptamer delivery. Biochimie. 145:45–52.
   PubMed Web of Science ®Google Scholar
• Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. 2008. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA. 105(45):17356–17361. eng.
   PubMed Web of Science ®Google Scholar
• Dong Y, Feng SS. 2005. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 26(30):6068–6076.
   PubMed Web of Science ®Google Scholar
• Eskandari Z, Kazdal F, Bahadori F, Ebrahimi N. 2018. Quality-by-design model in optimization of PEG-PLGA nano micelles for targeted cancer therapy. J Drug Deliv Sci Technol. 48:393–402.
   Web of Science ®Google Scholar
• Ferro-Flores G, Luna-Gutierrez M, Ocampo-Garcia B, Santos-Cuevas C, Azorin-Vega E, Jimenez-Mancilla N, Orocio-Rodriguez E, Davanzo J, Garcia-Perez FO. 2017. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT . Nucl Med Biol. 48:36–44.
   PubMed Web of Science ®Google Scholar
• Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. 1999. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 57(2):171–185. eng.
   PubMed Web of Science ®Google Scholar
• Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science. 263(5153):1600–1603.
   PubMed Web of Science ®Google Scholar
• Hao Y, Liu J, Jia Q, Sui J, Huang G. 2019. SN-38-loaded PLGA microspheres injected intratumorally for cancer: preparation, characterization and evaluation. J Drug Deliv Sci Technol. 53(101178):101178.
   Google Scholar
• Jin J, Sui B, Gou J, Liu J, Tang X, Xu H, Zhang Y, Jin X. 2014. PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells. PLoS One. 9(11):e112200.
   PubMed Web of Science ®Google Scholar
• Jin W, Qin B, Chen Z, Liu H, Barve A, Cheng K. 2016. Discovery of PSMA-specific peptide ligands for targeted drug delivery. Int J Pharm. 513(1–2):138–147.
   PubMedGoogle Scholar
• Khattabi AM, Talib WH, Alqdeimat DA. 2017. A targeted drug delivery system of anti-cancer agents based on folic acid-cyclodextrin-long polymer functionalized silica nanoparticles. J Drug Deliv Sci Technol. 41:367–374.
   Web of Science ®Google Scholar
• Kundu P, Das S, Chattopadhyay N. 2019. Managing efficacy and toxicity of drugs: targeted delivery and excretion. Int J Pharm. 565:378–390.
   PubMedGoogle Scholar
• Le D. 2015. Anti-tumor activity of docetaxel PLGA-PEG nanoparticles with a novel anti-HER2 scFv. J Nanomed Nanotechnol. 6:2.
   Google Scholar
• Liu D, Mori A, Huang L. 1992. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta. 1104(1):95–101.
   PubMedGoogle Scholar
• Liu Y, Li K, Liu B, Feng S-S. 2010. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials. 31(35):9145–9155.
   PubMed Web of Science ®Google Scholar
• Luo X, Yang Y, Kong F, Zhang L, Wei K. 2019. CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells. Int J Pharm. 564:340–349.
   PubMedGoogle Scholar
• Maghsoudi S, Shahraki BT, Rabiee N, Afshari R, Fatahi Y, Dinarvand R, Ahmadi S, Bagherzadeh M, Rabiee M, Tayebi L, et al. 2019. Recent advancements in aptamer-bioconjugates: sharpening Stones for breast and prostate cancers targeting. J Drug Deliv Sci Technol. 53:101146.
   Web of Science ®Google Scholar
• Mohammadian M, Kouchakzadeh H, Rahmandoust M, Mohammadian T. 2020. Targeted albumin nanoparticles for the enhancement of gemcitabine toxicity on cancerous cells. J Drug Deliv Sci Technol. 56:101503.
   Web of Science ®Google Scholar
• Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, Puglisi G. 2006. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 325(1–2):172–179.
   PubMedGoogle Scholar
• Noori Koopaei M, Khoshayand MR, Mostafavi SH, Amini M, Khorramizadeh MR, Jeddi Tehrani M, Atyabi F, Dinarvand R. 2014. Docetaxel loaded PEG-PLGA nanoparticles: optimized drug loading. Iran J Pharm Res. 13(3):819–833.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. 2004. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Rafiei P, Haddadi A. 2017. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine. 12:935–947.
   PubMed Web of Science ®Google Scholar
• Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ. 2001. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 19(9):2509–2516.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Teixeira M, Alonso MJ, Pinto MM, Barbosa CM. 2005. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur J Pharm Biopharm. 59(3):491–500.
   PubMed Web of Science ®Google Scholar
• Zale SEH, Troiano G, Ali MM, Hrkach J, Wright J, inventor; BIND Therapeutics, Inc. (Cambridge, MA, US), assignee. 2013. Drug loaded polymeric nanoparticles and methods of making and using same. United States patent 8617608.
   Google Scholar
• Zhang Z, Zhu Z, Yang D, Fan W, Wang J, Li X, Chen X, Wang Q, Song X. 2016. Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer. Oncol Lett. 12(2):1001–1006.
   PubMed Web of Science ®Google Scholar